All Articles
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
Late-Breaking HOPA News: T-cell Malignancies with CAR T-cell therapy
In November 2023, the FDA announced their investigation of reports of T-cell lymphomas from clinical trials and post-marketing adverse event data sources for CAR T-cell immunotherapies. In January 2024, the FDA issued Safety Labeling Change notification.
Pharmacist’s Application to Practice: Nirogacestat (Ogsiveo)
Brooke Lochridge, PharmD ,PGY-2 Oncology Pharmacy Resident, of Tristar Centennial Medical Center, Nashville, TN, and Colleen McCabe, PharmD, BCOP, Oncology Clinical Specialist, Sarcoma & Melanoma from Vanderbilt University Medical Center, Nashville, TN w
Pharmacist’s Application to Practice: Eflornithine for High-Risk Neuroblastoma
Taylor Gullickson, PharmD, PGY1 Pharmacy Resident and Alexis Kuhn, PharmD, BCOP, Pediatric Oncology Pharmacist, from Mayo Clinic Rochester, Minnesota write about Eflornithine for High-Risk Neuroblastoma.
Late-Breaking HOPA News: COMMANDS Study for Myelodysplastic Syndrome
The COMMANDS study was a phase 3, open-label, multicenter, randomized controlled trial. Patients were eligible for enrollment if they were 18 years or older, diagnosed with very low risk, low risk or intermediate risk MDS, ESA-naïve, and requiring red blo